BioSpace News Archive

Feb. 24, 2020 13:00 UTC CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people with kidney disease, today announced plans to release its fourth quarter and full-year 2019 financial results, on Tuesday, March 10, 2020 before the opening of the financial markets. Akebia will host a conference call at 9:00 a.m. Eastern Time on Tuesday, March 10th, to

Feb. 24, 2020 13:00 UTC Conference Call and Webcast Scheduled for Monday, March 2, 2020 at 8:30 AM ET NEW YORK--( BUSINESS WIRE )-- UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will report fourth quarter and full year 2019 financial results on Monday, March 2, 2020, prior to the open of the market. The ann

Corporate Headquarters Relocated to Lilly Gateway Labs in South San Francisco

Alkermes plc announced that its Chief Executive Officer, Richard Pops, will present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020 at 3:30 p.m. ET from Boston.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the fourth quarter and full year ended December 31, 2019.

Exact Sciences Corporation (NASDAQ: EXAS) (the “Company”) today announced an underwritten public offering of $850 million aggregate principal amount of convertible senior notes due 2028 (the “Notes”) pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) on Form S-3.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on its recent corporate activities and outlook.

Researchers at the University of Texas at Austin and the National Institutes of Health created the first 3D atomic scale map of the 2019 novel coronavirus.

Clovis Oncology, Inc. reported financial results for the quarter and year ended December 31, 2019, and provided an update on Clovis’ clinical development programs and regulatory and commercial outlook for 2020..

OTTAWA , Feb. 24, 2020 /CNW/ - The Canadian Medical Association (CMA) shares the sense of outrage expressed by the Alberta Medical Association (AMA) and is equally concerned with the state of health care in the province. At a time when the health care system is confronted with an aging population with complex health issues, destabilizing access to care is the wrong thing to